Get the Stockscreener App
29.46
0.57%
-0.17
Moderna Inc stock is traded at $29.46, with a volume of 12.28M.
It is down -0.57% in the last 24 hours and up +10.30% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$29.63
Open:
$29.46
24h Volume:
12.28M
Relative Volume:
1.10
Market Cap:
$11.51B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.3746
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+6.35%
1M Performance:
+10.30%
6M Performance:
+7.71%
1Y Performance:
-31.20%
1-Day Range:
$29.40
$30.43
1-Week Range:
$26.89
$30.43
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
29.46 | 11.58B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna to Host Investor Event – Analyst Day - York Dispatch
Bellevue Group AG Has $34.18 Million Stock Position in Moderna, Inc. $MRNA - MarketBeat
Banque Transatlantique SA Cuts Position in Moderna, Inc. $MRNA - MarketBeat
Moderna (NASDAQ:MRNA) Director Sells $13,910.40 in Stock - MarketBeat
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says - Proactive financial news
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Morningstar
ImmunityBio, Moderna among winners of EU drug recommendations this week - Seeking Alpha
EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike - TradingView
Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges - GuruFocus
Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating - marketscreener.com
MRNA: Jefferies Initiates Coverage with Hold Rating and $30 PT | - GuruFocus
Jefferies Initiates Coverage on Moderna With Hold Rating, $30 Price Target - marketscreener.com
Emergers: Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell - TradingView — Track All Markets
Jefferies initiates Moderna stock with Hold rating, $30 price target - Investing.com
Moderna Stock On Fire: Up 23% With 7-Day Winning Streak - Trefis
Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? - Stocktwits
Petition claims FDA oops! means COVID-19 vaccines misbranded - BioWorld MedTech
Moderna on track to extend gains for the seventh straight trading day - MSN
Moderna protects you from illness and poor vaccine information - WSBT
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.? - GuruFocus
Moderna (MRNA) Q1 2025 Earnings Call Transcript - The Globe and Mail
Covid Shots Slash ER Visits for Kids in CDC Study - Bloomberg.com
Is the Market Bullish or Bearish on Moderna Inc? - Benzinga
Moderna signs deal worth up to $503m with Nanexa - Pharmaceutical Technology
Moderna and Super Micro top S&P 500 short interest list — are they ripe for a squeeze? - MSN
Moderna Secures $1.5B Five-Year Loan from Ares Management Ahead of Strategy Update - Finviz
US in "big danger" of falling behind in vaccine tech amid funding cuts, skepticism: Moderna co-founder - Seeking Alpha
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewswire Inc.
Moderna Founder Warns US Doubts on Science Threaten Biotech Edge - Bloomberg.com
Moderna Stock Rockets 21% With 6-Day Winning Streak - Trefis
Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products - TradingView — Track All Markets
Researchers Identify Immune Trigger Behind Myocarditis After Covid Vaccination - Bloomberg.com
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Ames Tribune
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Livingston Daily
First Trust Advisors LP Has $34.02 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Amundi Sells 425,861 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna (MRNA) Under Scrutiny as FDA Investigates Vaccine Safety - GuruFocus
FDA examines possible adult deaths from Covid-19 shots in probe - The Straits Times
FDA expands COVID-19 shot safety probe to include adultsreport - Seeking Alpha
FDA probes deaths likely related to COVID vaccines across age groups - Reuters
FDA Probes If Covid Shots Might Be Linked to Deaths of Adults - Bloomberg.com
Moderna, Pfizer, and BioNTech stock briefly dips on FDA Covid vaccine probe - Investing.com Canada
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy? - Finviz
Global AI Infrastructure Shift Ignites Biotech Growth Phase - Investing News Network
Dir Hussain Files To Sell 504 Of Moderna Inc [MRNA] - TradingView
Ossiam Has $3.08 Million Stake in Moderna, Inc. $MRNA - MarketBeat
CFO Mock Acquires 24,373 Of Moderna Inc [MRNA] - TradingView
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Invesco Ltd. Has $195.92 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Lido Advisors LLC Sells 140,814 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):